Analysts Issue Forecasts for Edesa Biotech Q1 Earnings

Edesa Biotech, Inc. (NASDAQ:EDSA) – HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Edesa Biotech in a research report issued to clients and investors on Monday, November 3rd. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.30) for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Edesa Biotech’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for Edesa Biotech’s Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.26) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Edesa Biotech in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.00.

Edesa Biotech Stock Down 2.3%

EDSA opened at $1.70 on Tuesday. The firm has a market cap of $11.96 million, a price-to-earnings ratio of -1.29 and a beta of 0.07. Edesa Biotech has a 52 week low of $1.55 and a 52 week high of $4.49. The business’s 50 day moving average is $2.44 and its two-hundred day moving average is $2.25.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of EDSA. Stonepine Capital Management LLC acquired a new position in shares of Edesa Biotech in the first quarter valued at approximately $1,678,000. Velan Capital Investment Management LP acquired a new position in shares of Edesa Biotech in the first quarter valued at approximately $1,678,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of Edesa Biotech in the first quarter valued at approximately $1,525,000. Institutional investors and hedge funds own 5.50% of the company’s stock.

Edesa Biotech Company Profile

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.